Clinical Trial Update: Administration of Epstein Barr Virus - Specific Cytotoxic T-Lymphocytes to Metastatic EBV-Positive Nasopharygneal Cancer [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating administration of Epstein-Barr virus-specific cytotoxic T-lymphocytes to patients with metastatic EBV-positive nasopharyngeal …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• EBV-specific cytotoxic T lymphocytes (EBV-specific cytotoxic T lymphocytes)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Nasopharyngeal Cancer | Phase 1 | Status: COMPLETED